

Date: 17-03-2018

To

The Secretary,
The BSE Limited,
Mumbai-400 001.

Dear Sir/ Madam,

Sub: Rectified Discrepancies in Financial Result for the Quarter ended December 2017

With reference to your Email dated,9th March 2018 Segment Profit & Capital Employed Totaling Rectified in Financial Results Quarter Ended December 2017.

You are requested to consider the rectified Financial Results Quarter Ended December,2017.

Thanks & Regards,

Yours Faithfully,
For Trimurthi Limited.


Authorized Signatory.



TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956

TRIMURTHI LIMITED
(Formerly Known as TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED)
SCHEDULE III OF THE COMPANIES ACT 2013

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER III AND 9 MONTHS ENDED 31ST DECEMBER, 2017



PART-I

Particulars	(Rs. In Lakhs)				
	Quarter Ended			Nine Months Ended	
	31-12-2017	30/09/2017	31-12-2016	31-12-2017	31-12-2016
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited
I. Income From Operations					
Net Sales / Income from Operations	104.54	27.25	79.73	182.67	277.26
Other Income	0.06	0.05	31.81	2.22	58.17
II. Total Income	104.60	27.30	111.54	184.89	335.43
III. Expenses					
a. Consumption of Raw Material	-Nil-	-Nil-	Nil	-Nil-	-Nil-
b. Purchase of Traded Goods/Shares	111.17	2.79	69.93	114.25	306.68
c. (Increase)/Decrease in stock in trade and work in Progress	(29.36)	(0.53)	6.98	(7.97)	(34.31)
d. Employee benefits expense	7.52	5.47	5.11	18.80	15.83
e. Rent	0.95	0.55	0.35	2.25	1.95
f. Finance Cost	0.00	0.00	0.00	0.00	0.00
g. Depreciation	(0.00)	4.01	3.46	7.70	8.75
h. Other Expenditure	3.41	2.74	2.47	11.51	15.52
Total	93.68	15.03	88.31	146.53	314.33
Profit/ (Loss) before Exceptional and Tax (III-IV)	10.92	12.27	23.23	38.36	21.10
V. Exceptional Items	Nil	Nil	Nil	Nil	Nil
VI. Profit/ (Loss) before tax (V-VI)	10.92	12.27	23.23	38.36	21.10
VII. Tax expense:	2.16	2.60	6.70	9.81	6.58
(1) Current tax	2.81	2.63	7.66	10.14	7.65
(2) Deferred tax	(0.65)	(0.03)	(0.96)	(0.33)	(1.07)
VIII. Net Profit/ (Loss) for the period from continuing operations (VII-VIII)	8.76	9.67	16.54	28.54	14.52
IX. Profit/(loss) from discontinued operations	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
X. Tax expenses of discontinued operations	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
XI. Profit/(loss) from Discontinued operations (after tax) (X-XI)	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
XII. Profit/(loss) for the period (IX+XII)	8.76	9.67	16.54	28.54	14.52
XIII. Other Comprehensive Income					
A. (i) Items that will not be reclassified to profit or loss	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
(ii) Income tax relating to items that will not be reclassified to profit or loss	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
B. (i) Items that will be reclassified to profit or loss	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
(ii) Income tax relating to items that will be reclassified to profit or loss	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
XIV. Total Comprehensive Income for the period (XIII+XIV) Comprising Profit (Loss) and Other comprehensive Income for the period)	8.76	9.67	16.54	28.54	14.52
XV. Earnings per equity share (for continuing operation):					
(1) Basic	0.11	0.12	0.20	0.35	0.18
(2) Diluted	0.11	0.12	0.20	0.35	0.18
XVI. Earnings per equity share (for discontinuing operation):					
(1) Basic	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
(2) Diluted	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
XVII. Earnings per equity share (for discontinuing & continuing operation):					
(1) Basic	0.11	0.12	0.20	0.35	0.18
(2) Diluted	0.11	0.12	0.20	0.35	0.18



TRIMURTHI LIMITED

(Formerly known as Trimurthi Drugs & Pharmaceuticals Ltd.)
4-4-231/1/2/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956

TRIMURTHI LIMITED
(Formerly Known as TRIMURTHI DRUGS & PHARMACEUTICALS LIMITED)

SCHEDULE III OF THE COMPANIES ACT 2013

PART-II



Particulars	Quarter Ended			Nine Months Ended	
	31-12-2017	30-09-2017	31-12-2016	31-12-2017	31-12-2016
	UnAudited	UnAudited	UnAudited	UnAudited	UnAudited
A. Particulars Of Share Holding					
1. Public Share Holding					
- Number of Shares	2900600	2900600	2849600	2900600	2849600
- Percentage of shareholding	35.81%	35.81%	35.18%	35.81%	35.18%
2. Promoters and promoter group shareholding					
a. Pledged / encumbered					
- No of Equity Shares	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
- Percentage of Shares (of the shareholding of promoter and promoter group)	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
- Percentage of Shares (of the total share capital of the company)	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
b. Non encumbered					
- No of Equity Shares	5199400	5199400	5250400	5199400	5250400
- Percentage of Shares (of the shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of Shares (of the total share capital of the company)	64.19%	64.19%	64.82%	64.19%	64.82%

Particulars	3 Months Ended (31/12/2017)
B. Investor Complaints	
Pending at the beginning of the quarter	-NIL-
Received during the quarter	-NIL-
Disposed during the quarter	-NIL-
Remaining unsolved during the quarter	-NIL-

Segment Reporting

Particulars	Quarters ended			Nine Months Ended	
	31-12-2017	30-09-2017	31-12-2016	31-12-2017	31-12-2016
	UnAudited	UnAudited	Audited	UnAudited	UnAudited
1. Segment Revenue					
a. Pharma Business	0.00	0.00	0.00	0.00	0.00
b. Financial Services	19.91	21.64	23.19	63.06	47.40
c. Investments	0.00	0.00	9.47	0.00	9.47
d. Trading in Shares	84.70	5.51	81.11	121.83	278.67
Total	104.60	27.16	113.77	184.89	335.54
Less: Inter Segment Revenue	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
Net Sales/ Income From Operations	104.60	27.16	113.77	184.89	335.54
2. Segment Profits (Before tax & Interest From Each Segment)					
a. Pharma Business	0.00	0.00	0.00	0.00	0.00
b. Financial Services	15.48	14.62	13.21	45.86	22.19
c. Investments	0.00	0.00	7.24	0.00	9.47
d. Trading in Shares	(10.44)	(2.49)	2.78	(7.50)	(10.41)
Total	5.05	12.13	23.23	38.36	21.25
Less:					
i. Interest	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
ii. Other Un-allocable expenses net off	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
iii. Un-allocable Income	-Nil-	-Nil-	-Nil-	-Nil-	-Nil-
Total Profit Before Tax	5.05	12.13	23.23	38.36	21.25
3. Capital Employed					
a. Pharma Business	0.00	0.00	0.00	0.00	0.00
b. Financial Services	(43.44)	(33.82)	181.55	601.72	653.06
c. Investments	0.00	0.00	(180.35)	184.34	179.34
d. Trading in Shares	46.64	46.24	21.86	398.72	326.14
Total	3.20	12.42	23.06	1184.78	1158.54

Notes:

- The format for the Unaudited quarterly results as prescribed in SEBI Circular CRI/CFD/CMD/15/2015 dated November 30, 2015 has been modified to comply with the requirements of SEBI Circular CRI/CFD/FAC/62/2016 dated July 5, 2016 and exemption as given under clause 2.6.1(ii) has been availed. Hence, figures of corresponding previous quarter and previous year have not been provided.
- There is a possibility that these quarterly financial results may require adjustment before compiling the final Ind AS financial statements as of and for the year ending March 31, 2018 due to changes in financial reporting requirements arising from new or revised standards or interpretations issued by MCA or changes in the use of one or more optional exemptions from retrospective application of certain Ind AS as permitted under Ind AS 101.
- Previous period figures have been regrouped, wherever necessary, for the purpose of comparison.
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on Saturday, 10th February, 2018.
- The Standalone Unaudited Financial Results have been prepared and subjected to Limited Review by the Statutory Auditors in accordance with Indian Accounting Standards (Ind-AS) as notified by Ministry of Corporate Affairs; Regulation 33 of SEBI (LODR) Regulations, 2015 and Schedule III Division II of Companies Act, 2013. The Limited Review was carried out by Statutory Auditors for the Quarter ended 30th September, 2017. The Ind AS Complaint figures for the Corresponding previous Quarter ended 30th September, 2016 have not been subject to review or audit, however the Company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
- The results are also available on the website of the Company
- Reconciliation between Financial Results previously reported (referred to as PREVIOUS GAAP) and Ind AS for the Quarter ended 31st December, 2017

Particulars	Quarter Ended 31/12/2017	Nine Months Ended 31/12/2016
Net Profit as per previous GAAP	8.76	14.51
Increase in profit due to:		
Fair Value impact for financial instrument	NIL	NIL
Net Profit as per Ind AS After Tax	8.76	14.51
Other Comprehensive Income	NIL	NIL
Total Comprehensive Income under Ind AS	NIL	NIL



Place : Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Date : 10-02-2018

Trimurthi Limited
4-4-231/172/ABC, Inderbagh, Sultanbazar,
Hyderabad - 500 095, T.S. INDIA. | Tel: 040 24757370
Email : info@trimurthidrugs.com
Website : www.trimurthidrugs.com
CIN No : L67120TG1994PLC018956